The role of teriparatide in sequential and combination therapy of osteoporosis.

Détails

Ressource 1Télécharger: 24896070.pdf (414.32 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_E04BD37E015C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The role of teriparatide in sequential and combination therapy of osteoporosis.
Périodique
Swiss Medical Weekly
Auteur(s)
Meier C., Lamy O., Krieg M.A., Mellinghoff H.U., Felder M., Ferrari S., Rizzoli R.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
144
Pages
w13952
Langue
anglais
Notes
Publication types: Journal Article Publication Status: epublish PDF: Review Article
Résumé
Osteoporosis is complicated by the occurrence of fragility fractures. Over past years, various treatment options have become available, mostly potent antiresorptive agents such as bisphosphonates and denosumab. However, antiresorptive therapy cannot fully and rapidly restore bone mass and structure that has been lost because of increased remodelling. Alternatively recombinant human parathyroid hormone (rhPTH) analogues do increase the formation of new bone material. The bone formation stimulated by intermittent PTH analogues not only increases bone mineral density (BMD) and bone mass but also improves the microarchitecture of the skeleton, thereby reducing incidence of vertebral and nonvertebral fractures. Teriparatide, a recombinant human PTH fragment available in Switzerland, is reimbursed as second-line treatment in postmenopausal women and men with increased fracture risk, specifically in patients with incident fractures under antiresorptive therapy or patients with glucocorticoid-induced osteoporosis and intolerance to antiresorptives. This position paper focuses on practical aspects in the management of patients on teriparatide treatment. Potential first-line indications for osteoanabolic treatment as well as the benefits and limitations of sequential and combination therapy with antiresorptive drugs are discussed.
Pubmed
Web of science
Open Access
Oui
Création de la notice
08/08/2014 20:40
Dernière modification de la notice
20/08/2019 17:04
Données d'usage